www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/14796

Title: Market uptake of orphan drugs - a European analysis
Authors: Picavet, E.
Annemans, L.
Cleemput, I.
Cassiman, D.
Simoens, S.
Issue Date: 2012
Publisher: WILEY-BLACKWELL
Citation: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 37 (6), p. 664-667
Abstract: What is known and Objective: Variations in market uptake of an orphan drug have important implications with respect to access to care and inequality of treatment. Therefore, the aim of this study was to quantify both the sales and volume uptake of orphan drugs in Europe and to assess whether a countrys gross domestic product (GDP) and/or health technology assessment (HTA) influences the orphan drugs market uptake. Methods: We analysed the numbers of orphan drugs launched and the sales and volume uptake for 17 orphan drugs in 23 European countries from 2001 until the beginning of 2010 using the IMS Health database. Countries were clustered based on GDP and the availability of a formal HTA-organization. Results and Discussion: The uptake of orphan drugs varied across European countries. The highest volumes and contributions of orphan drugs in the first year occurred in countries with a high GDP (and implicitly, a higher budget for healthcare), independently of the existence of an HTA-organization. In contrast, in countries with a low GDP, orphan drugs were less available when there was a formal HTA-organization. There, budgetary restrictions can cause the exclusion of less cost-effective orphan drugs. What is new and Conclusion: We observed substantial variation in the market uptake of orphan drugs. Such variation may have important implications with respect to access to care and inequality of treatment. The uptake of orphan drugs could be promoted through the clinical added value of orphan drugs (CAVOD) project and various conditional pricing and reimbursement mechanisms.
Notes: [Picavet, E.] Katholieke Univ Leuven, Res Ctr Pharmaceut Care & Pharmacoecon, Fac Pharmaceut Sci, B-3000 Louvain, Belgium. [Annemans, L.] Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium. [Cleemput, I.] Belgian Hlth Care Knowledge Ctr, Brussels, Belgium. [Cassiman, D.] Univ Hosp Leuven, Dept Hepatol, Louvain, Belgium.
URI: http://hdl.handle.net/1942/14796
DOI: 10.1111/j.1365-2710.2012.01364.x
ISI #: 000310601200009
ISSN: 0269-4727
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A520.85 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.